Exel’s Q4 EBIT was soft relative to estimates, yet demand doesn’t seem to abate and in our view the ...
Marimekko delivered strong Q4 figures, outpacing our and consensus estimates.
Redeye comments on Stillfront’s Q4-results which was in line with our expectations and company guida...
Redeye sees a solid Q4 report beating our forecasts regarding both sales and EBIT, driven by strong ...
Redeye has updated its forecasts, which primarily include near-term adjustments due to the absence o...
Redeye’s preliminary revisions indicate a slight increase in sales forecasts but a near-term reducti...
Redeye comments on Medivir's Q4 report.
BactiQuant A/S (“BactiQuant” or the “Company”) has developed a technology that monitors bacterial co...
Calliditas lead project in the clinical pipeline besides Nefecon/TARPEYO is Setanaxib targeting prim...
Redeye comments on Sleep Cycle’s Q4 report, which was more or less in line with our estimates.
Freja eID's strong commercial momentum through 2021 laid a promising foundation to fuel its financia...
Although we do not expect results overnight, we believe IAR Systems is taking the steps needed to ge...
Solteq reports Q4 results on February 17th. We foresee some continued softness due to the current en...
Atria reported Q4 adjusted EBIT of EUR 10.3m, -19% / -13% versus Refinitiv consensus and Nordea, res...
Probi redovisade ett kvartal präglat av framgångar i Europa och Asien medan utmaningarna i region Am...
Redeye is pleased to see another quarter of sound performance, despite rather challenging conditions...
Redeye argues that the lower-than-anticipated sales do not reflect the long-term case of Episurf and...
Redeye provides an initial take on Alelion’s Q4 report, where sales did not live up to our expectati...
Redeye is cautiously optimistic to yesterday’s licensing agreement between Nexstim and Magnus Medica...
Redeye states that the Q4 report from FlexQube was strong with record sales and order intake.
